• Patrick Wallace, Laurie Bezjian Wallace, Sarah Tamura, Kirk Prochnio, Kyle Morgan, and Douglas Hemler.
• From the Rocky Vista University College of Osteopathic Medicine, Parker, Colorado (PW, LBW); Department of Emergency Medicine, University Nevada Las Vegas, Las Vegas, Nevada (PW); Department of Family Medicine, Mike O'Callaghan Military Medical Center, Las Vegas, Nevada (LBW); and Star Spine and Sport, Golden, Colorado (ST, KP, KM, DH).
• Am J Phys Med Rehabil. 2020 Aug 1; 99 (8): 689-693.

ObjectiveThe aim of the study was to investigate the efficacy of ultrasound-guided platelet-rich plasma in reducing sacroiliac joint disability and pain.DesignProspective nonrandomized interventional study analyzing 50 patients with low back pain secondary to sacroiliac joint dysfunction. Platelet-rich plasma was injected into the sacroiliac joint under ultrasound guidance. Oswestry Disability Index and Numeric Rating Scale were measured at baseline, 2 wks, 4 wks, 3 mos, and 6 mos after injection.ResultsThe mean reduction in Oswestry Disability Index and Numeric Rating Scale scores were significantly reduced at 6 mos after injection compared with baseline values (mean = -9.79%, 95% CI = -6.06 to -13.52) and (mean = -1.94, 95% CI = -1.14 to -2.78), respectively. All timeframes showed significant mean reduction compared with baseline, but overall improvement tapers off after 4 wks with no statistically significant reduction from 4 wks to 3 mos or 3 to 6 mos.ConclusionsUltrasound-guided platelet-rich plasma injections in the sacroiliac joint are effective at reducing disability and pain with most improvement seen within 4 wks after injection and with sustained reduction at 6 mos.

18 keywords...

hide…